Brote ampollar en un paciente psoriásico
DOI:
https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v26i3.1148Resumen
.
Descargas
Referencias
Yancey KB, Egan CA. Pemphigoid: clinical,histologic, immunopathologic, and therapeuticconsiderations. JAMA 2000;284(3):350-6. DOI: https://doi.org/10.1001/jama.284.3.350
Mutasim DF, Bilic M, Hawayek LH, et al.Immunobullous diseases. J Am Acad Dermatol2005;52(6):1029-43. DOI: https://doi.org/10.1016/j.jaad.2004.11.064
McKenna JK, Leiferman KM. Dermatologicdrug reactions. Immunol Allergy Clin North Am2004;24(3):399-423, vi. DOI: https://doi.org/10.1016/j.iac.2004.03.007
Smith EP, Taylor TB, Meyer LJ, et al. Antigenidentification in drug-induced bullouspemphigoid. J Am Acad Dermatol 1993;29(5Pt 2):879-82. DOI: https://doi.org/10.1016/0190-9622(93)70262-R
Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report andreview of literature. J Drugs Dermatol 2006;5(6):562-4.
Wojnarowska F, Kirtschig G, Highet AS,et al. Guidelines for the management ofbullous pemphigoid. Br J Dermatol 2002;147(2):214-21. DOI: https://doi.org/10.1046/j.1365-2133.2002.04835.x
Joly P, Roujeau JC, Benichou J, et al. Acomparison of oral and topical corticosteroidsin patients with bullous pemphigoid. N Engl JMed 2002;346(5):321-7. DOI: https://doi.org/10.1056/NEJMoa011592
Ahmed AR. Intravenous immunoglobulintherapy for patients with bullous pemphigoidunresponsive to conventionalimmunosuppressive treatment. J Am AcadDermatol 2001;45(6):825-35 DOI: https://doi.org/10.1067/mjd.2001.116337
Leonardi CL. Efalizumab: an overview. J AmAcad Dermatol 200349(2 Suppl):S98-104 DOI: https://doi.org/10.1016/S0190-9622(03)01141-1
Descargas
Compartir artículo
Publicado
Número
Sección
Licencia
Derechos de autor 2006 Daniela Malieni, Mariana Guzzi Maqueda, Isabel Hidalgo Parra, Gastón Galimberti, Alicia Kowalczuk, Ricardo Galimberti
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
